biostudies-literatureUnknown13(12)Kook HW<b>Background</b>: Unlike therapy-related myeloid neoplasms, therapy-related acute lymphoblastic leukaemia (tr-ALL) is poorly defined due to its rarity. However, increasing reports have demonstrated that tr-ALL is a distinct entity with adverse genetic features and clinical outcomes. <b>Methods:</b> We compared the clinicopathological characteristics and outcomes of patients diagnosed with tr-ALL (<i>n</i> = 9) or <i>de novo</i> ALL (dn-ALL; <i>n</i> = 162) at a single institution from January 2012 to March 2021. The mutational landscapes of eight tr-ALL and 63 dn-ALL patients were compared from a comprehensive next-generation sequencing panel. <b>Results</b>: All tr-ALL patients had the B-cell phenotype. The most frequently mutated genes were <i>IKZF1</i> (37%), <i>CDKN2A</i> (14%), <i>SEJournal of Cancer3326-3332https://www.ebi.ac.uk/biostudies/studies/S-EPMC9516015biostudies-literatureTherapy-related Acute Lymphoblastic Leukaemia has a Unique Genetic Profile Compared to <i>De Novo</i> Acute Lymphoblastic Leukaemia.PMC9516015Shin SMin YHKim JJKook HWCheong JWPark MRJang JELee STfalseTherapy-related Acute Lymphoblastic Leukaemia has a Unique Genetic Profile Compared to <i>De Novo</i> Acute Lymphoblastic Leukaemia.<b>Background</b>: Unlike therapy-related myeloid neoplasms, therapy-related acute lymphoblastic leukaemia (tr-ALL) is poorly defined due to its rarity. However, increasing reports have demonstrated that tr-ALL is a distinct entity with adverse genetic features and clinical outcomes. <b>Methods:</b> We compared the clinicopathological characteristics and outcomes of patients diagnosed with tr-ALL (<i>n</i> = 9) or <i>de novo</i> ALL (dn-ALL; <i>n</i> = 162) at a single institution from January 2012 to March 2021. The mutational landscapes of eight tr-ALL and 63 dn-ALL patients were compared from a comprehensive next-generation sequencing panel. <b>Results</b>: All tr-ALL patients had the B-cell phenotype. The most frequently mutated genes were <i>IKZF1</i> (37%), <i>CDKN2A</i> (14%), <i>SE2022-01-01T00:00:00Z20222025-04-22T03:41:24.75Z2025-04-05T20:46:49.744ZS-EPMC95160153618690110.7150/jca.76719